跳至主要内容
临床试验/ACTRN12622000021774
ACTRN12622000021774已完成未知

Immunomodulatory effects following focal ablation of localized prostate cancer with irreversible electroporation

St. Vincent's Private Hospital0 个研究点目标入组 30 人开始时间: 2022年1月12日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • Patients must meet the following inclusion criteria to be eligible to participate in the study
  • Male, aged 18 years or over
  • Confirmed adenocarcinoma of prostate with organ confined (less than or equal to cT2) disease and Gleason 3 + 4 = 7 or Gleason 4 + 3 = 7 prostate cancer.
  • Currently scheduled for either IRE or radical prostatectomy
  • No previously diagnosed prostate cancer
  • No use of immunosuppressive drugs
  • Ability to give written informed consent, participate in and comply with study
  • Able to attend blood collection centre at appropriate time.

排除标准

  • Patients who meet any of the following exclusion criteria are not eligible to participate in the study
  • Use of immunosuppressive drugs
  • Previous diagnosis of prostate cancer
  • Inability/ incapacity to provide own consent
  • Inability/ incapacity for venous blood collection
  • PSA >20ng/ml
  • greater than or equal to cT3 on DRE

研究者

发起方
St. Vincent's Private Hospital

相似试验